Financhill
Back

Novavax 10K Form

Sell
32

NVAX
Novavax

Last Price:
18.67
Seasonality Move:
5.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

Receive NVAX News And Ratings

See the #1 stock for the next 7 days that we like better than NVAX

NVAX Financial Statistics

Sales & Book Value

Annual Sales: $1.15B
Cash Flow: $-195.48M
Price / Cash Flow: 0
Annual Sales: $-5.33
Price / Book: 0

Profitability

EPS (TTM): -19.46000
Net Income (TTM): $-1.48B
Gross Margin: $0
Return on Equity: -1465.25%
Return on Assets: -55.27%

Novavax Earnings Forecast

Key Novavax Financial Ratios

  • The Gross Profit Margin over the past 21 years for NVAX is 0.00%.
  • The Selling, General & Administrative Expenses for NVAX have been equal to 26.03% of Gross Profit Margin.
  • The Research & Development expenses have been 221.11% of Revenue.
  • The Interest Expense is -1.21% of Operating Income.
  • The Net Earning history of NVAX is -152.12% of Total Revenues.
  • Per Share Earnings over the last 26 years have been positive in 11 years.

Novavax Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: NVAX
CUSIP: 670002
Website: novavax.com

Debt

Debt-to-Equity Ratio: -0.78
Current Ratio: 0.99
Quick Ratio: 0.73

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 2.76

NVAX Technical Analysis vs Fundamental Analysis

Sell
32
Novavax (NVAX) is a Sell

Is Novavax a Buy or a Sell?

  • Novavax stock is rated a Sell
    The current Novavax [NVAX] share price is $18.57. The Score for NVAX is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.